Research programme: human monoclonal antibodies - Medarex/Seagen
Alternative Names: Human monoclonal antibodies research programme - Medarex/Seagen; Research programme: anti-cancer monoclonal antibodies - Medarex/SeagenLatest Information Update: 18 Dec 2023
At a glance
- Originator Medarex; Seattle Genetics
- Developer Medarex; Seagen
- Class Monoclonal antibodies
- Mechanism of Action Antibody-dependent cell cytotoxicity
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Cancer